Posted by Michael Wonder on 24 May 2019
Final NICE guidance issued for Akcea’s Tegsedi
24 May 2019 - Akcea Therapeutics UK has announced that NICE has published a final guideline for its nerve damage drug, Tegsedi (inotersen).
The Highly Specialised Technologies Guidance is for the treatment of stage I or II polyneuropathy in adult patients with hereditary transthyretin amyloidosis.
It follows the positive final evaluation document published last month recommending that patients in England with this rare, inherited, severely debilitating and fatal disease, can access the treatment on the NHS.
